CervoMed financials
$2.88+7.87%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $8.7K | $322.6K | $1.8M | $1.9M | $2.2M | $1.9M | $3.3M | $2.3M | $2.5M | $1.5M |
| Gross profit | $0.00 | $0.00 | $8.7K | $322.6K | $1.8M | $1.9M | $2.2M | $1.9M | $3.3M | $2.3M | $2.5M | $1.5M |
| Gross margin | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$6.7M | -$8.1M | -$8.3M | -$8.0M | -$6.6M | -$5.3M | -$7.2M | -$5.4M | -$3.0M | -$2.6M | -$2.5M | -$2.7M |
| Net income | -$6.6M | -$8.0M | -$8.1M | -$7.7M | -$6.3M | -$4.9M | -$6.7M | -$4.8M | -$2.3M | -$2.5M | -$2.4M | $2.2M |
| Net margin | — | — | −92680.4% | −2395.3% | −356.1% | −255.2% | −310.2% | −245.1% | −70.4% | −107.1% | −94.9% | 140.9% |
| Diluted EPS | $-0.64 | $-0.86 | $-0.87 | $-0.84 | $-0.70 | $-0.56 | $-0.77 | $-0.55 | $-0.27 | $-0.41 | $-0.40 | $-0.70 |
| EBITDA | -$6.7M | -$8.1M | -$8.3M | -$8.0M | -$6.6M | -$5.3M | -$7.2M | -$5.4M | -$3.0M | -$2.6M | -$2.5M | -$2.7M |
| Operating cash flow | -$6.9M | -$8.0M | -$6.6M | -$6.5M | -$6.5M | -$3.9M | -$8.1M | -$4.9M | -$2.2M | -$1.4M | -$2.5M | -$1.5M |
| Free cash flow | -$6.9M | -$8.0M | -$6.6M | -$6.5M | -$6.5M | -$3.9M | -$8.1M | -$4.9M | -$2.2M | -$1.4M | -$2.5M | -$1.5M |
| Diluted shares | 10.2M | 9.3M | 9.3M | 9.3M | 9.0M | 8.7M | 8.7M | 8.7M | 8.7M | 6.2M | 5.8M | 3.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $22.5M | $7.9M | $8.2M | $9.4M | $8.3M | $10.5M |
| Short-term investments | $2.5M | $5.0M | $12.6M | $17.9M | $25.2M | $24.7M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $26.0M | $15.1M | $22.9M | $30.6M | $38.1M | $38.6M |
| Total liabilities | $3.0M | $4.5M | $4.7M | $4.6M | $4.6M | $3.9M |
| Shareholders' equity | $23.0M | $10.6M | $18.2M | $26.0M | $33.4M | $34.6M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology